Context

Targovax is a clinical stage immuno-oncology group developing oncolytic viruses to target hard-to-treat solid tumours.

The Company’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It activates the immune system to generate tumour-specific immune responses.

Targovax has established collaborations with major pharmaceuticals companies and highly recognized academic centers, including Merck & Co, AstraZeneca, Cancer Research Institute, and the Ludwig Cancer Research.

In June 2020, Targovax reported 12-month data for its ONCOS-102 program in mesothelioma, which is currently being tested in a randomized phase I/II study.

This capital raise will be used to finance ongoing ONCOS-102 clinical studies (mesothelioma study to completion, part 2 of a melanoma study, a colorectal cancer study) and the manufacturing of clinical material for ONCOS-102 trials. It will also expand the current pipeline with pre-clinical data on next-generation ONCOS viruses, novel Mutant RAS (MutRAS) projects and ONCOS constructs.

About Targovax

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax’ lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.
ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and checkpoint inhibitors.

Discover Targovax

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Erik Furnes

Equity Capital Markets

Erik furnes picture

Vincent Meunier

Investment Banking

Vincent Meunier photo

Håkon Benjaminsen

Investment Banking

Håkon Benjaminsen photo

Grégoire Angleys

Equity Capital Markets

Gregoire Angleys photo

Pierre Sertour

Equity Capital Markets

Pierre Sertour photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }

Privacy Preference Center